Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Toxicol Lett. 2019 Dec 15;317:45-52. doi: 10.1016/j.toxlet.2019.09.016. Epub 2019 Sep 23.
This study involved an attempt to establish a new photosafety screening system for dermally-applied chemicals consisting of a reactive oxygen species (ROS) assay and an in vitro skin permeation test. The ROS assay was undertaken to evaluate photoreactivity of six test compounds, acridine (ACD), furosemide (FSM), hexachlorophene (HCP), 8-methoxypsoralen (MOP), norfloxacin (NFX), and promethazine (PMZ), and the in vitro skin permeation test was conducted to obtain steady-state concentration (C) values of test compounds in removed rat skin. All test compounds were photoreactive based on ROS generation under simulated sunlight exposure. In particular, ROS generation from ACD was high compared with other test compounds, and photoreactivity of ACD was deduced to be potent. The C values of ACD, HCP, MOP, and PMZ were over 50 μg/mL, and skin exposure to FSM and NFX was found to be extremely low. Upon these findings, ACD was judged to be highly phototoxic. The rank for phototoxic risk of test compounds based on photoreactivity and in vitro skin exposure was mostly in agreement with outcomes on their in vivo phototoxicity in rats. The proposed strategy, an alternative to animal testing, would be efficacious for photosafety evaluation of drug candidates in early stages of pharmaceutical development.
本研究旨在建立一种新的经皮应用化学物质光稳定性筛选系统,包括活性氧(ROS)测定和体外皮肤渗透试验。ROS 测定用于评估 6 种受试化合物(吖啶(ACD)、呋塞米(FSM)、六氯酚(HCP)、8-甲氧基补骨脂素(MOP)、诺氟沙星(NFX)和奋乃静(PMZ))的光反应性,体外皮肤渗透试验用于获得受试化合物在去除大鼠皮肤中的稳态浓度(C)值。所有受试化合物在模拟阳光照射下均产生 ROS,具有光反应性。特别是 ACD 产生的 ROS 生成量高于其他受试化合物,表明 ACD 的光反应性很强。ACD、HCP、MOP 和 PMZ 的 C 值均超过 50μg/ml,而 FSM 和 NFX 在皮肤中的暴露量极低。根据这些发现,ACD 被判断为具有高度光毒性。基于光反应性和体外皮肤暴露的受试化合物的光毒性风险等级与它们在大鼠体内的光毒性结果基本一致。该策略是对动物试验的替代方法,可有效评估药物研发早期候选药物的光安全性。